4.4 • 637 Ratings
🗓️ 25 October 2024
⏱️ 56 minutes
🧾️ Download transcript
Mark Goldberg is a Managing Partner and Co-Founder at Chemistry, a $350M fund announced just yesterday with the mission to lead the best seed and Series A rounds. Before Chemistry, Mark was a Partner at Index Ventures, where he led early stage investments in Plaid, Bridge, Pilot, Anrok and Persona. Prior to Index Ventures, Mark was one of the first business hires at Dropbox.
In Today’s Episode with Mark Goldberg We Discuss:
1. The Truth About Multi-Stage Firms:
Why are portfolio services there to help the investing partners and not the founders?
What are the most broken elements within a multi-stage firm?
How does decision-making break down in large partnerships?
When is the right time to work with multi-stage firms? When is not?
2. From Boutique High Margins to Commoditised Low Margins:
With the immense amount of cash that has entered VC, will returns simply get worse?
Who will be the winners in the next 10 years of venture?
Who will be the losers? What can they do today to change this?
What element of the future of venture are not enough people spending time on?
3. Lessons from Leading Unicorn Company Rounds:
What happens to all the unicorns with insanely high prices they cannot grow into?
What has been Mark’s biggest hit? What did he learn?
What has been his biggest miss? How did that change his go-forward approach?
Does Mark agree that 90% of VC do not add value?
Click on a timestamp to play from that location
0:00.0 | I think one of the dirty secrets of multi-stage investing is that portfolio services teams are not for founders. |
0:05.8 | They're for the VCs. |
0:06.7 | They are a way to make something unscalable scale. |
0:10.5 | So we have a very light reserve model. |
0:12.4 | Peanut buttering all of your reserves and every pro rata round that gets done is not a good thing for the founder. |
0:18.4 | The biggest mistake is when you try to make consensus decisions at |
0:21.7 | the early stage, I think you end up with consensus funds. This is 20 VC with me, Harry Stebbings, |
0:26.5 | and today we have a very special show for you. On Wednesday this week, we saw a new fund announcement |
0:31.6 | in the form of chemistry, a new $350 million seed and series A firm from Mark Goldberg, Ethan Kurzweil and Christina Shen. |
0:40.3 | Today, I sit down with Mark to unpack it all. |
0:43.3 | For those that do not know, prior to chemistry, Mark was a partner at Index Ventures, |
0:47.3 | where he led early stage investments in Plaid, Bridge, Pilot, Anrock and Persona, to name a few. |
0:53.3 | But before we dive in, what do Henry Ford and |
0:56.0 | AI have in common? Neither could change the world without automation. In the future, there will be |
1:01.6 | two types of businesses, those that have automated and those that wish they had. UiPath, |
1:07.1 | the undisputed leader in automation, is taking us into the era of agenic automation. |
1:12.6 | UiPath's new AI agents don't just follow rules. |
1:15.6 | They think, they make decisions, they work alongside the world's most powerful software robots, |
1:21.6 | already trusted by over 10,000 businesses. |
1:24.6 | If agentic automation sounds new, just think of UiPath as more growth, |
1:29.2 | not more overhead platform or happier customers, happier employees platform. Whatever you want |
1:35.3 | AI to do for your business, agenic automation with UiPath will make it happen. Try UiPath's new |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from The Twenty Minute VC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of The Twenty Minute VC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.